ALFA Finder| Management target | Net Profit 20.0% FY27 |
|---|
| Revenue growth | 21.9% YoY for Q1 FY27. |
|---|---|
| Margins | EBITDA margin at 22%, up 190bps YoY; PAT margin 14.2%. |
| Demand visibility | Strong domestic pharmaceutical market growth above 10% expected. |
| Management confidence | High; confident in meeting FY27 targets and outperforming IPM. |
Growth
Q1 Revenue at INR422Cr (+21.9% YoY); PAT at INR60Cr (+30.1% YoY); EBITDA margins expanded 190bps to 22%.
Outlook
Maintained FY27 guidance of 15% organic revenue growth and 20% PAT growth; recently commissioned new hormone facility.
Risks
Geopolitical Southeast Asia risks impacting raw material costs; volatility in input/ancillary expenses mentioned.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 21.9% (= BEAT)
- Guided 20% PAT growth → delivered 30.1% (= BEAT)
- Guided 20% EBITDA margin → delivered 22% (= BEAT)
Earnings Call Transcript filed with BSE, NSE: CORONA. Summary written with AI assistance from the document.
Corona Remedies Ltd: key numbers
- Share price
- ₹2,387.30
- Market cap
- ₹14,601 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 70.5×Sector 43.8×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 4.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Corona Remedies Ltd
All →Corona Remedies Legal & Regulatory
Corona Remedies received an NPPA demand notice of Rs 4.88 Crore for alleged DPCO 2013 price violations. The company is evaluating it and reports no material financial impact.
- Value
- ₹4.88 Cr
Corona Remedies Earnings Call Transcript: Key Takeaways
CORONA delivered robust revenue growth of 22% YoY, outperforming the Indian pharmaceutical market by focusing on chronic segments. Management maintains a growth target of 1.5x the market rate.
- Call
- Guides 15% growth
Corona Remedies Investor Presentation: Key Takeaways
Q2FY27 revenue ₹441.2Cr (+22.2%), PAT ₹60.3Cr (+15.3%); H1 revenue ₹863.6Cr (+22.0%), PAT ₹120.4Cr (+22.2%). Chronic-led growth, outpacing IPM.
Corona Remedies Results Update
Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.
Corona Remedies Q2 FY27 Results: Net Profit ₹60.3 Cr, Up 15.3% YoY
Corona Remedies Ltd reported revenue from operations of ₹441.2 Cr (+22.2% YoY) and net profit of ₹60.3 Cr (+15.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹60.3 Cr · +15.3% YoY
Corona Remedies Business Update
Corona Remedies received GMP Compliance Certification from Brazil's ANVISA for its OSD and Hormone facilities in Ahmedabad. This validates export eligibility to the Brazilian pharmaceutical market.